Overview
Updated 14 Jul 2026
Irene Ghobrial, MD, is Senior Vice President for Experimental Medicine at Dana-Farber Cancer Institute. The public record shows 1,124 publications with 46,485 citations (h-index 101), centered on Multiple Myeloma Research and Treatments, Chronic Lymphocytic Leukemia Research, Protein Degradation and Inhibitors. It also documents an investigator role on 16 registered clinical trials, industry payments reported by 21 companies, 12 NIH-funded awards (2007–2026).
- Most recent indexed publication: 2026 · Blood cancer discovery
- Top research focus: Multiple Myeloma Research and Treatments
- 16 registered trials on ClinicalTrials.gov
- Open Payments reporting from 21 companies
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 58 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 365.
Clinical & industrytrials, payments and federal funding
Public positionssourced statements on record
- Presented on "Unmet Need" at the FDA Oncologic Drugs Advisory Committee (ODAC) meeting
March 15, 2024, regarding CARVYKTI (ciltacabtagene autoleucel) for relapsed/refractory multiple myeloma
2024provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →targetedonc.com ↗
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 16 registered studies on ClinicalTrials.gov. The most recent:
- CAR- PRISM (PRecision Intervention Smoldering Myeloma)
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2Active, not recruitingNCT05767359 - Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
Sponsor: Dana-Farber Cancer Institute
InvestigatorRecruitingNCT03689595 - Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
Sponsor: Dana-Farber Cancer Institute
InvestigatorPhase 2Active, not recruitingNCT03236428
Industry payments
Updated 14 Jul 2026
21 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year202511 payments$29,209openpaymentsdata.cms.gov ↗
- Janssen Global Services, LLCProgram year20251 payment
- SANOFI-AVENTIS U.S. LLCProgram year20251 payment
NIH funding
Updated 14 Jul 2026
12 NIH research awards on record, funded 2007–2026 per NIH RePORTER. The latest:
- Defining immune determinants oftransformation in MGUS/SMM
Dana-Farber Cancer Inst
FY2026$959,573P01CA306849
Congress activity
Updated 14 Jul 2026
148 congress contributions (2004–2026) across AACR, ASCO, ASH per OpenAlex. The most recent:
- Abstract 2015: Single-cell atlas of tumor and immune cells in disease progression from MGUS to MM
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- New Insights into the Role of Clonotypic B Cells in Plasma-cell Neoplasia.
Blood cancer discovery
2026 - A Longitudinal Comprehensive Biospecimen and Clinical Data Repository for Cancer Early Detection: The InAdvance Study.
Cancer epidemiology, biomarkers & prevention
2026 - Pharmacological targeting of IRF4 as a therapeutic strategy for multiple myeloma.
Nature chemical biology
2026
Most-cited worksby citation count (OpenAlex)
- 01
- 02BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc2,849 citations2011
- 03
- 04
- 05Targeting Apoptosis Pathways in Cancer Therapy1,335 citations2005
Contact
No public contact details on file. This person's NPPES record doesn't include a practice address or telephone number. Why? →
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Residency in Internal Medicine
Wayne State University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗ - Hematology/Oncology Fellowship
Mayo Clinic College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗
Editorial & leadership rolesjournal and society appointments
- Professor of Medicine
Harvard Medical School
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- Director
Clinical Investigator Research Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →labs.dana-farber.org ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Secondary affiliationsappointments beyond the home institution
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →dana-farber.org ↗
Media & interviewspress, podcasts and appearances
- Hematologic Oncology Update podcast (iHeartRadio)
interview with Neil Love MD, Multiple Myeloma Update 1
2019verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →iheart.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
- The Patient Story
video interview on MGUS, smoldering, and active myeloma treatment/research
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →thepatientstory.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- LinkedIn
linkedin.com/in/ireneghobrial
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Irene-Ghobrial
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/ireneghobrial
Mentions by otherswhere others cite or feature them
- LinkedIn
linkedin.com/posts/dana-farber-cancer-institute_congratulations-to-irene-ghobrial-md-dr-activity-7247353405940142083-pGVn
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/labghobrial
- YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Nikhil Munshi, MD
Dana-Farber Cancer Institute
- 1,801
- publications
- 152
- h-index
- 8
- trials
Patrick Wen, MD
Dana-Farber Cancer Institute
- 1,915
- publications
- 146
- h-index
- 27
- trials
Geoffrey Shapiro, MD
Dana-Farber Cancer Institute
- 2,055
- publications
- 116
- h-index
- 24
- trials
Patrick Ott, MD
Dana-Farber Cancer Institute
- 616
- publications
- 82
- h-index
- 8
- trials